Get the Stockscreener App
8.60
2.60%
-0.23
After Hours:
8.61
0.010
+0.12%
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 - Marketscreener.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities - Defense World
Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report - Simply Wall St
Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility - Yahoo Finance
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlook - Investing.com
ENTA (Enanta Pharmaceuticals) Accounts Receivable : $6.65 Mil (As of Sep. 2024) - GuruFocus.com
Enanta Pharmaceuticals Inc. (ENTA) reports earnings - Quartzy
Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet - Simply Wall St
Enanta Pharmaceuticals (STU:9EP) Cash Flow from Operations : €-83.19 Mil (TTM As of Jun. 2024) - GuruFocus.com
Enanta stock touches 52-week low at $8.45 amid market challenges - Investing.com Canada
4 Analysts Assess Enanta Pharma: What You Need To Know - Benzinga
Leerink raises Enanta price target to $12 from $10, keeps rating - Investing.com UK
ENTA (Enanta Pharmaceuticals) Investments And Advances : $42.51 Mil (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Machinery, Furniture, Equipme - GuruFocus.com
ENTA (Enanta Pharmaceuticals) EBITDA per Share : $-5.02 (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Future 3-5Y EPS without NRI G - GuruFocus.com
Enanta Pharmaceuticals expands immunology portfolio - BioWorld Online
Enanta Pharmaceuticals shares target cut, rating held ahead of clinical trial results - Investing.com UK
ENTA (Enanta Pharmaceuticals) 3-Year Book Growth Rate : -23.20% (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) GF Value Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Debt-to-Asset : 0.13 (As of Jun. 2024) - GuruFocus.com
Enanta Pharmaceuticals Reports Q4 2024 Financials - TipRanks
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2024 - Marketscreener.com
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 - BioSpace
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot - Marketscreener.com
Enanta Pharmaceuticals Inc Reports Q4 Loss of $1.36 Per Share, R - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Cash From Other Investing Act - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Free Cash Flow per Share : $-4.75 (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) EBITDA : $-104.08 Mil (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) 14-Day RSI : 29.52 (As of Nov. 25, 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Debt-to-Revenue : 0.70 (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Issuance of Stock : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Change In Prepaid Assets : $1.81 Mil (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Net Issuance of Debt : $-7.17 Mil (TTM As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Forward Rate of Return (Yackt - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Other Long-Term Liabilities : $143.54 Mil (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Cash, Cash Equivalents, Marke - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) 5-Day RSI : 26.30 (As of Nov. 25, 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Other Current Liabilities : $32.30 Mil (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Long-Term Capital Lease Obligation : $48.14 Mil (As of Jun. 2024) - GuruFocus.com
ENTA (Enanta Pharmaceuticals) Purchase Of Investment : $-413.40 Mil (TTM As of Jun. 2024) - GuruFocus.com
Trend Tracker for (ENTA) - Stock Traders Daily
Enanta Pharma's Earnings Outlook - Benzinga
Enanta Pharmaceuticals (FRA:9EP) 3-Year Dividend Growth Rat - GuruFocus.com
Head to Head Analysis: CannTrust (OTCMKTS:CNTTF) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) - Defense World
ARMISTICE CAPITAL, LLC Adjusts Stake in Enanta Pharmaceuticals I - GuruFocus.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
(ENTA) Proactive Strategies - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Assenagon Asset Management S.A. Trims Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
(ENTA) On The My Stocks Page - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Short Interest Up 14.7% in October - MarketBeat
Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck - The Globe and Mail
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable - Yahoo Finance
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress boosts stock outlook - Investing.com
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):